Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;22(5):565-567.
doi: 10.1016/S1473-3099(22)00125-6. Epub 2022 Mar 11.

CD24Fc: an emerging COVID-19 therapy

Christina M Eckhardt  1 , Max R O'Donnell  2
Affiliations
Comment

CD24Fc: an emerging COVID-19 therapy

Christina M Eckhardt et al. Lancet Infect Dis. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

References

    1. Welker J, Pulido JD, Catanzaro AT, et al. Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00058-5. published online March 11. - DOI - PMC - PubMed
    1. Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197. - PMC - PubMed
    1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed
    1. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384:1491–1502. - PMC - PubMed

Substances